Amgen (XTER:AMG) Long-Term Debt : €51,225 Mil (As of Sep. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Amgen Long-Term Debt?

Amgen's Long-Term Debt for the quarter that ended in Sep. 2024 was €51,225 Mil.

Amgen's quarterly Long-Term Debt declined from Mar. 2024 (€55,256 Mil) to Jun. 2024 (€53,062 Mil) and declined from Jun. 2024 (€53,062 Mil) to Sep. 2024 (€51,225 Mil).

Amgen's annual Long-Term Debt increased from Dec. 2021 (€29,401 Mil) to Dec. 2022 (€35,262 Mil) and increased from Dec. 2022 (€35,262 Mil) to Dec. 2023 (€57,927 Mil).

Amgen Long-Term Debt Historical Data

The historical data trend for Amgen's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Long-Term Debt Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

24,255.00

27,039.69

29,401.47

35,262.18

57,926.89

Amgen Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial															55,320.48	57,926.89	55,256.12	53,061.69	51,225.45

Amgen (XTER:AMG) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Amgen Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Amgen's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (XTER:AMG) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico 1AMGN:Italy AMGd:UK AMG:Germany AMG:Germany AMG:Germany AMGN:Chile AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.